Laura Espinosa
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Laura Espinosa has a total of 36 co-authors. Here are the top co-authors by number of shared publications:
- Maria Jose Martinez Urrutia
Department of Pediatric Surgery, Children's Hospital, La Paz, Madrid, Spain
2 shared publications - Pedro Lopez Pereira
Section of Pediatric Urology, Hospital Universitario La Paz, Madrid, Spain
2 shared publications A. Alonso Melgar
Nefrología Infantil La Paz, Madrid, Spain
1 shared publicationA. Peña Carrión
Nefrología Infantil La Paz, Madrid, Spain
1 shared publication- A. Peña Carrión
Nefrología, Hospital Infantil La Paz, Paseo de la Castellana 261, Madrid 28046, Spain
1 shared publication - Amir Shabaka
Nephrology Department, Hospital Universitario La Paz, Madrid, Spain
1 shared publication
Latest Publications
- Open Access
Next-Generation Sequencing Defines a Molecularly Confirmed ARPKD Core Within the Broader PKHD1-Associated Disease Spectrum
Background/Objectives: Autosomal recessive polycystic kidney disease (ARPKD) is a severe ciliopathy caused by biallelic pathogenic variants in PKHD1, characterized by variable renal and hepatobiliary involvement. The widespread use of next-generation sequencing (NGS) has revealed a large number of rare PKHD1 variants, creating major challenges in distinguishing molecularly confirmed ARPKD from a broader spectrum of PKHD1-associated disease. Methods: We performed an integrated clinical and molecular analysis of 68 individuals referred for suspected ARPKD. Using phase-aware and family-informed ACMG classification, patients were stratified into three genetically defined groups: 40 with molecularly confirmed ARPKD (biallelic pathogenic, likely pathogenic or segregation-supported VUS-LP variants in trans), 10 with biallelic PKHD1 variants of uncertain pathogenicity, and 18 monoallelic carriers. Genotype–phenotype correlations were restricted to the molecularly confirmed ARPKD group. Results: Among the 40 molecularly confirmed ARPKD patients, 17 (42.5%) carried two loss-of-function (LoF) alleles, 16 (40%) carried one LoF allele, and 7 (17.5%) carried only non-LoF alleles. A strong allele-dose effect was observed. Neonatal or infantile onset occurred in 88% of LoF/LoF patients, compared with 56% of LoF/non-LoF and 29% of non-LoF/non-LoF individuals (p < 0.001). Progression to renal replacement therapy occurred in 65%, 31%, and 0% of patients (p = 0.002). In contrast, hepatobiliary disease was highly prevalent across all genotype classes and showed no significant association with LoF burden. Conclusions: Phase-aware and family-informed interpretation of PKHD1 variants distinguishes a molecularly confirmed ARPKD core from a broader PKHD1 variant spectrum. Within confirmed ARPKD, loss-of-function allele burden is the primary determinant of renal and perinatal severity, whereas hepatic disease is largely independent of truncating allele burden. These findings refine diagnosis, prognosis, and genetic counseling in the genomic era.
Open AccessNext-Generation Sequencing Defines a Molecularly Confirmed ARPKD Core Within the Broader PKHD1-Associated Disease Spectrum
Background/Objectives: Autosomal recessive polycystic kidney disease (ARPKD) is a severe ciliopathy caused by biallelic pathogenic variants in PKHD1, characterized by variable renal and hepatobiliary involvement. The widespread use of next-generation sequencing (NGS) has revealed a large number of rare PKHD1 variants, creating major challenges in distinguishing molecularly confirmed ARPKD from a broader spectrum of PKHD1-associated disease. Methods: We performed an integrated clinical and molecular analysis of 68 individuals referred for suspected ARPKD. Using phase-aware and family-informed ACMG classification, patients were stratified into three genetically defined groups: 40 with molecularly confirmed ARPKD (biallelic pathogenic, likely pathogenic or segregation-supported VUS-LP variants in trans), 10 with biallelic PKHD1 variants of uncertain pathogenicity, and 18 monoallelic carriers. Genotype–phenotype correlations were restricted to the molecularly confirmed ARPKD group. Results: Among the 40 molecularly confirmed ARPKD patients, 17 (42.5%) carried two loss-of-function (LoF) alleles, 16 (40%) carried one LoF allele, and 7 (17.5%) carried only non-LoF alleles. A strong allele-dose effect was observed. Neonatal or infantile onset occurred in 88% of LoF/LoF patients, compared with 56% of LoF/non-LoF and 29% of non-LoF/non-LoF individuals (p < 0.001). Progression to renal replacement therapy occurred in 65%, 31%, and 0% of patients (p = 0.002). In contrast, hepatobiliary disease was highly prevalent across all genotype classes and showed no significant association with LoF burden. Conclusions: Phase-aware and family-informed interpretation of PKHD1 variants distinguishes a molecularly confirmed ARPKD core from a broader PKHD1 variant spectrum. Within confirmed ARPKD, loss-of-function allele burden is the primary determinant of renal and perinatal severity, whereas hepatic disease is largely independent of truncating allele burden. These findings refine diagnosis, prognosis, and genetic counseling in the genomic era.
- Open Access
- 1 March 2020
- Published by The Permanente Federation in The Permanente Journal
- Vol. 24 (1)
Importance of Assessing Compliance with Conservative Treatment of Primary Hyperoxaluria Type 1: A Case Report of a Patient with I244T/c.969-3C>G Mutation
Paloma Gutiérrez Medina, MD; Laura Espinosa Román, PhD Perm J...
- 1 March 2020
- Published by The Permanente Federation in The Permanente Journal
- Vol. 24 (1)
Open AccessImportance of Assessing Compliance with Conservative Treatment of Primary Hyperoxaluria Type 1: A Case Report of a Patient with I244T/c.969-3C>G Mutation
Paloma Gutiérrez Medina, MD; Laura Espinosa Román, PhD Perm J...
- 1 December 2016
- Published by Elsevier in European Urology Supplements
- Vol. 15 (9) , 402-407
Renal Transplant and Reconstructive Surgery
- 1 December 2016
- Published by Elsevier in European Urology Supplements
- Vol. 15 (9) , 402-407
Renal Transplant and Reconstructive Surgery
- 1 January 2015
- Published by Elsevier in Transplantation Proceedings
- Vol. 47 (1) , 38-41
Renal Transplantation in Children With Nephrotic Syndrome in the First Year of Life
- 1 January 2015
- Published by Elsevier in Transplantation Proceedings
- Vol. 47 (1) , 38-41
Renal Transplantation in Children With Nephrotic Syndrome in the First Year of Life
- 31 October 2008
- Published by Elsevier in Anales de Pediatría Continuada
- Vol. 6 (5) , 249-257
Tubulopatías
- 31 October 2008
- Published by Elsevier in Anales de Pediatría Continuada
- Vol. 6 (5) , 249-257
Tubulopatías
- 1 April 2008
- Published by Elsevier in Anales de Pediatría Continuada
- Vol. 6 (2) , 93-97
Pruebas de función renal
- 1 April 2008
- Published by Elsevier in Anales de Pediatría Continuada
- Vol. 6 (2) , 93-97
Pruebas de función renal
- 18 September 2007
- Published by Springer Nature in Pediatric Nephrology
- Vol. 22 (11) , 1875-1880
Steroid-resistant nephrotic syndrome: long-term evolution after sequential therapy
We present a retrospective study of 30 children of mean age 3.02 ± 1.81 years with steroid-resistant nephrotic syndrome (SRNS) treated with intravenous injection of methylprednisolone plus orally administered prednisone; 24 children also received cyclophosphamide (CP). Sixteen were resistant to steroids from the beginning, and 14 after a mean of 11.26 ± 16.61 months. The initial histological diagnosis was: 18 minimal change disease (MCD), 11 focal segmental glomerulosclerosis (FSGS) and one diffuse mesangial proliferative glomerulonephritis (DMPG). Total remission was achieved in 22 patients (73.3%), partial response in three (10%) and no response in five (16.6%), two of whom were brothers carrying an NPHS2 gene double mutation. There was no difference in response between the MCD and FSGS patients; the only patient with DMPG did not respond. Only initial resistance was a sign of bad prognosis. At follow-up (6.4 ± 3.6 years from last pulse), 21/22 were still in remission, 14/21 were without treatment. Six patients required cyclosporine or mycophenolate mofetil because of steroid dependence. Two non-responders developed end-stage renal failure (ESRF); the remaining patients maintained normal glomerular filtration. The treatment was well tolerated. In conclusion, most of the patients treated with sequential therapy consisting of methylprednisolone (MP) (100%) and CP (80%) showed remission and preserved renal function, but 20% developed steroid dependence.
- 18 September 2007
- Published by Springer Nature in Pediatric Nephrology
- Vol. 22 (11) , 1875-1880
Steroid-resistant nephrotic syndrome: long-term evolution after sequential therapy
We present a retrospective study of 30 children of mean age 3.02 ± 1.81 years with steroid-resistant nephrotic syndrome (SRNS) treated with intravenous injection of methylprednisolone plus orally administered prednisone; 24 children also received cyclophosphamide (CP). Sixteen were resistant to steroids from the beginning, and 14 after a mean of 11.26 ± 16.61 months. The initial histological diagnosis was: 18 minimal change disease (MCD), 11 focal segmental glomerulosclerosis (FSGS) and one diffuse mesangial proliferative glomerulonephritis (DMPG). Total remission was achieved in 22 patients (73.3%), partial response in three (10%) and no response in five (16.6%), two of whom were brothers carrying an NPHS2 gene double mutation. There was no difference in response between the MCD and FSGS patients; the only patient with DMPG did not respond. Only initial resistance was a sign of bad prognosis. At follow-up (6.4 ± 3.6 years from last pulse), 21/22 were still in remission, 14/21 were without treatment. Six patients required cyclosporine or mycophenolate mofetil because of steroid dependence. Two non-responders developed end-stage renal failure (ESRF); the remaining patients maintained normal glomerular filtration. The treatment was well tolerated. In conclusion, most of the patients treated with sequential therapy consisting of methylprednisolone (MP) (100%) and CP (80%) showed remission and preserved renal function, but 20% developed steroid dependence.
- 1 April 2007
- Published by Elsevier in Journal of Pediatric Urology
- Vol. 3 (4) , S58-58
Growing up with a bladder augmentation
- 1 April 2007
- Published by Elsevier in Journal of Pediatric Urology
- Vol. 3 (4) , S58-58
Growing up with a bladder augmentation